Year In Review 2016 MPN

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor, Jakafi® (Ruxolitinib), has led to an effective alleviation of these symptoms in many patients with PV, impacting both disease burden and quality of life. The identification of certain gene conditions that contribute to MPNs have led to improvements in diagnosis and stratifying risk. Ongoing trials will further define the role of JAK inhibitors in MPNs as well as evaluate combination therapies and new targeted therapies.

CancerConnect News coverage of advances in the management of MPNs included the following key developments:

Polycythemia Vera News

Myelofibrosis News

Essential Thrombocythemia

MPN Side Effect News


Click here for CURRENT MPN NEWS

Learning More About Myeloproliferative Neoplasms

  • Sign up for monthly MPN newsletters here.
  • Join the CancerConnect online support group to join ongoing discussions with other individuals affected by PV, ET and myelofibrosis here.
  • Follow CancerConnect on Facebook and Twitter.

Copyright © 2017 CancerConnect. All Rights Reserved.


More news and in-depth Myeloproliferative Neoplasms MPN information.

CancerConnect Cancer Commuity & Discussions

Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS